Research programme: cancer immunotherapeutics - PCI Biotech/Ultimovacs

Drug Profile

Research programme: cancer immunotherapeutics - PCI Biotech/Ultimovacs

Latest Information Update: 02 Feb 2016

Price : $50

At a glance

  • Originator PCI Biotech; Ultimovacs AS
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Jan 2016 Preclinical trials in Cancer in Norway (unspecified route)
  • 27 Jan 2016 PCI Biotech and Ultimovacs agree to co-develop cancer immunotherapeutics in Norway for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top